Burden of primary sclerosing cholangitis in Sweden (2002–2020): Incidence, outcomes, healthcare utilization, and costs
HRU and healthcare costs for patients with PSC in Sweden were substantial and significantly increased after diagnosis. Effective therapies are needed to reduce disease progression and economic burden.
Authors
- Annika Bergquist (ORCID: https://orcid.org/0000-0002-3858-6241)
- Nandita Kachru (ORCID: https://orcid.org/0000-0002-2754-0723)
- Martina Aldvén
- Helena Skröder (ORCID: https://orcid.org/0000-0001-8318-7445)
- Emilie Toresson Grip (ORCID: https://orcid.org/0000-0002-2630-9503)
- Hannes Hagström (ORCID: https://orcid.org/0000-0002-8474-1759)
- O. Ström
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Gilead Sciences (United States) (US)
- Quantify Research (Sweden) (SE)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1097/hc9.0000000000000858
- Citations
- 1
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 1.32